Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alliance Pharmaceutical Corp.
Development, license, supply agreement signed for Oxygent
June 15th, 2005
Alliance Pharmaceutical Corp. (ALLP), through its subsidiary PFC Therapeutics, LLC, and Beijing Double-Crane Pharmaceutical Co., Ltd., have entered into a development, license and supply agreement for the development of Oxygent in The People's Republic of China (PRC). Pursuant to the agreement, Double-Crane will make an upfront license fee payment and certain milestone and royalty payments to Alliance. Double-Crane will conduct clinical trials in the PRC, in accordance with international guidelines, to receive marketing approval for Oxygent in the PRC. Alliance will have the right to use any data derived from the clinical trials in other countries....
Source: Physician Law Weekly (2005-06-15)
|
